News

Karen Onel, MD, one of the lead investigators of the ACR's recent JIA treatment guidelines updates, explains important changes, treating patients with glucocorticoids, and the continued unmet needs in pediatric rheumatology.

Free or total 25(OH)D serum levels were not associated with psoriasis disease severity in this small study of biologic-naïve patients.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 12, 2021.

Investigators examined the effect that pulsed low-intensity ultrasonography had on symptom relief and tibiofemoral articular cartilage thickness among patients with knee osteoarthritis.

Trauma patients and patients treated with combination ABX therapy were at an increased risk of C difficile infections.

“Kawasaki disease continues to be an area of evolving understanding in clinical treatment,” said Mark Gorelik, MD, lead investigator of the guideline.

More than 50% of patients with classified SLE at Washington University’s Lupus Clinic exhibit clinically meaningful and persistent depression and anxiety symptoms over time.

Titled, "Biosimilars in Rheumatology: Past, Present, and Future," this 3-part video series explores the origins of biosimilars, where we are currently, and hypothesizes about the future of biosimilars in the United States.

In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.

When patients undergo surgery for hip and knee replacements, adjustment to their rheumatoid arthritis care may be required. Test your knowledge of how to manage patients undergoing these types of surgery in this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending March 5, 2021.

The American College of Rheumatology (ACR) has published guidance regarding the management of juvenile idiopathic arthritis, with emphasis placed on the treatment of systemic JIA and oligoarthritis, as well as non-pharmacologic therapies.

The American College of Rheumatology releases 2 new guidelines for treating patients with juvenile idiopathic arthritis.

Aspartyl-alanyl-diketopiperazine (Ampion), an intra-articular injection, works to regulate immune responses that are connected to pain, inflammation, and joint damage in patients with osteoarthritis of the knee.

In rheumatoid arthritis, a treat-to-target approach aims for remission or low disease activity within the first 3 months. However, investigators noted that improvements continued to increase throughout the 52-week period.

New recommendations were released by ACR and AAHKS regarding perioperative management of antirheumatic medications for patients with rheumatic diseases undergoing these procedures.

"For many years we lacked access to novel therapeutics in SLE and our outcomes frequently reflected this," stated Jack Arnold, MBBS, MRCP. "However, with new targeted therapies, we appear to be entering a new era where treatment decisions will require more nuanced thought."

The long-term success of any psoriatic arthritis treatment may be predictable as early as 3 months if a timely assessment and adjustment of disease management is prioritized.

“This dramatic change in healthcare delivery led to significant challenges amongst healthcare management teams, healthcare professionals as well as patients, especially during the early phases of implementation," investigators stated.

Results indicated that a brief methotrexate withdrawal after COVID-19 vaccine doses may improve immunogenicity in patients with rheumatoid arthritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 25, 2021.

Susan Shenoi, MBBS, MS, discusses the recent developments in pediatric rheumatology as well as new therapies and guidelines for treating juvenile idiopathic arthritis.

The American College of Rheumatology has recently updated its recommendations on COVID-19 booster vaccines. Test your knowledge of the latest advice on COVID-19 boosters and how they should be administered with this quiz.

Study provides supportive data to confirm the pathogenic role of NEU1 in proliferative lupus nephritis.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 18, 2021.

Up to 30% of patients with psoriasis eventually develop inflammatory synovio-entheseal (SE) inflammation.

Though psoriasis often precedes psoriatic arthritis, some studies have shown that the time to transition from psoriasis to PsA had not been fully explained by genetic factors alone.

Arthur Kavanaugh, MD, provides a year in review, including new developments, in rheumatoid arthritis as well as his thoughts on the use of biosimilars.

Arthur Kavanaugh, MD, explains the recent developments in psoriatic arthritis and spondyloarthritis, as well as what rheumatologists should look forward to in 2022.

Arthur Kavanaugh, MD, discusses the Rheumatology Winter Clinical Symposium, which runs from February 16 – 19.